Ironwood Pharmaceuticals, Inc. - Class A
$4.23
$0.06 (+1.44%)
$4.20Day Range$4.48
Key Statistics
Market Cap
$698.96M
Shares Outstanding
165.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 3, 2010
Round Lot
100
Locale
US
Trading Data
Day Open
$4.27
Day High
$4.48
Day Low
$4.20
Volume
3.49M
VWAP
$4.28
Prev Close
$4.17
Transactions
--
Acc. Volume
--
About Ironwood Pharmaceuticals, Inc. - Class A
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
PHARMACEUTICAL PREPARATIONSSIC 2834100 employees100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110617-621-7722IPO Feb 3, 2010US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001446847
- Composite FIGI
- BBG000GBZ3J2
- Share Class FIGI
- BBG001SNZLM7
- Ticker Root
- IRWD
- SIC Code
- 2834
About Ironwood Pharmaceuticals, Inc. - Class A (IRWD) Stock
Ironwood Pharmaceuticals, Inc. - Class A (IRWD) closed the 2026-09-17 session at $4.23, up 1.44% versus the previous close (+0.06). The stock opened at $4.27 and traded between $4.20 and $4.48 during that session. Session trading volume was 3.5M shares. The volume-weighted average price (VWAP) is $4.28.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Ironwood Pharmaceuticals, Inc. - Class A has a market capitalization of $699.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. IRWD is listed on the XNAS exchange. The company employs approximately 100 people. Ironwood Pharmaceuticals, Inc. - Class A is headquartered in BOSTON, MA. The recorded listing date is 2010-02-03.
On this page you can find market IRWD stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.